{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:05:44Z","timestamp":1793423144075,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Geriatric Nursing"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.gerinurse.2025.05.010","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T05:37:52Z","timestamp":1748065072000},"page":"103371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Anti-amyloid immunotherapies for Alzheimer\u2019s disease: Administration, side effects, and overall framework"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5327-9200","authenticated-orcid":false,"given":"Zahra","family":"Sadruddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-6650","authenticated-orcid":false,"given":"Kristofer","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Bilsborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Sciba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Falk","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-1868","authenticated-orcid":false,"given":"Madison","family":"Shyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hinojosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Colby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1459-8416","authenticated-orcid":false,"given":"Karen","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Julian","family":"Martinez-Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0676-002X","authenticated-orcid":false,"given":"Paul E.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gerinurse.2025.05.010_bib0001","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1212\/CON.0000000000001131","article-title":"Alzheimer Disease","volume":"28","author":"McDade","year":"2022","journal-title":"Continuum: Lifelong Learn Neurol"},{"issue":"4","key":"10.1016\/j.gerinurse.2025.05.010_bib0002","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 alzheimer\u2019s disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimer\u2019s & Dement"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0003","article-title":"Therapeutic strategies targeting amyloid-\u03b2 in Alzheimer\u2019s disease","volume":"16","author":"Pinheiroa","year":"2019","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.1016\/j.gerinurse.2025.05.010_bib0004","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JAD-220046","article-title":"Safety and efficacy of monoclonal antibodies for Alzheimer\u2019s Disease: A systematic review and meta-analysis of published and unpublished clinical trials","volume":"87","author":"Lacorte","year":"2022","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"1","key":"10.1016\/j.gerinurse.2025.05.010_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13311-014-0313-y","article-title":"\u03b2-amyloid peptides and amyloid plaques in Alzheimer\u2019s disease","volume":"12","author":"Gouras","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105208","article-title":"Aggregation and structure of amyloid \u03b2-protein","volume":"151","author":"Ono","year":"2021","journal-title":"Neurochem Int"},{"issue":"2","key":"10.1016\/j.gerinurse.2025.05.010_bib0007","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0008","series-title":"These highlights do not include all the information needed to use ADUHELM\u00ae safely and effectively","year":"2021"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0009","series-title":"These Highlights Do Not Include All the Information Needed to Use LEQEMBI TM Safely and Effectively","year":"2023"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0010","series-title":"These highlights do not include all the information needed to use KISUNLA safely and effectively","year":"2024"},{"issue":"1","key":"10.1016\/j.gerinurse.2025.05.010_bib0011","article-title":"Impact of anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer\u2019s disease: a focus on Aducanumab and Lecanemab","volume":"14","author":"Shi","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.gerinurse.2025.05.010_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s Disease","volume":"388","author":"van Dyck","year":"2022","journal-title":"New England J Med"},{"issue":"6","key":"10.1016\/j.gerinurse.2025.05.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0014","article-title":"Time saved\u201d As a demonstration of clinical meaningfulness and illustrated using the Donanemab TRAILBLAZER-ALZ study findings","author":"Dickson","year":"2023","journal-title":"JPAD"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0015","first-page":"1","article-title":"Weiner M. Aducanumab: appropriate use recommendations","author":"Cummings","year":"2021","journal-title":"J Prevent Alzheimer\u2019s Dis"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0016","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prevent Alzheimer\u2019s Dis"},{"issue":"18","key":"10.1016\/j.gerinurse.2025.05.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"New England J Med"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0018","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy","author":"Barakos","year":"2022","journal-title":"J Prevent Alzheimer\u2019s Disease"},{"issue":"1","key":"10.1016\/j.gerinurse.2025.05.010_bib0019","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2021","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.gerinurse.2025.05.010_bib0020","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.22.28461","article-title":"Amyloid-related imaging abnormalities: an update","volume":"220","author":"Roytman","year":"2022","journal-title":"Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.gerinurse.2025.05.010_bib0021","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.gerinurse.2025.05.010_bib0022","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-022-00574-4","article-title":"ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies","volume":"17","author":"Raulin","year":"2022","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.630502","article-title":"Lipid transport to physiopathology and therapeutics","volume":"15","author":"Husain","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1326784","article-title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","volume":"18","author":"Doran","year":"2024","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.gerinurse.2025.05.010_bib0026","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.dadm.2016.02.004","article-title":"Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer\u2019s disease","volume":"2","author":"Carlson","year":"2016","journal-title":"Alzheimer\u2019s & Dement Diagnos Assessm Disease Monitor"},{"issue":"2","key":"10.1016\/j.gerinurse.2025.05.010_bib0027","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prevent Alzheimer\u2019s Disease"},{"issue":"9","key":"10.1016\/j.gerinurse.2025.05.010_bib0028","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1002\/alz.14108","article-title":"Considering challenges for the new Alzheimer's drugs: clinical, population, and health system perspectives","volume":"20","author":"Walsh","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0029","series-title":"Questions and answers on the approval and marketing authorisation of Leqembi (lecanemab)","year":"2023"},{"issue":"10","key":"10.1016\/j.gerinurse.2025.05.010_bib0030","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.17219\/acem\/194003","article-title":"Survival time in Alzheimer\u2019s disease: an overlooked measure of safety and efficacy of disease-modifying therapies","volume":"33","author":"Kurkinen","year":"2024","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.gerinurse.2025.05.010_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jradnu.2024.04.004","article-title":"Ethical issues around treatment-induced amyloid-related imaging abnormalities in Alzheimer's disease","author":"Daly","year":"2024","journal-title":"J Radiol Nurs"}],"container-title":["Geriatric Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197457225002022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197457225002022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T05:54:01Z","timestamp":1754459641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197457225002022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":31,"alternative-id":["S0197457225002022"],"URL":"https:\/\/doi.org\/10.1016\/j.gerinurse.2025.05.010","relation":{},"ISSN":["0197-4572"],"issn-type":[{"value":"0197-4572","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-amyloid immunotherapies for Alzheimer\u2019s disease: Administration, side effects, and overall framework","name":"articletitle","label":"Article Title"},{"value":"Geriatric Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gerinurse.2025.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103371"}}